OPKO Health (NASDAQ:OPK) Hits New 12-Month Low – Time to Sell?

Shares of OPKO Health, Inc. (NASDAQ:OPK) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $1.11 and last traded at $1.1150, with a volume of 1866323 shares traded. The stock had previously closed at $1.17.

OPKO Health News Summary

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Director John A. Paganelli purchased 10,000 shares at about $1.14, increasing his stake to 394,340 shares; insider buying can signal management confidence and offer short‑term support. SEC Filing
• Positive Sentiment: Barrington Research kept an Outperform/Buy stance on OPK, which may sustain interest from growth and penny‑stock investors despite other negative headlines. Barrington Article
• Neutral Sentiment: Zacks published thematic commentary noting OPKO’s strengths (RAYALDEE sales, partnerships) but flagged revenue declines and concentration risk — useful context for longer‑term holders evaluating risk/reward. Zacks Hold Article
• Negative Sentiment: Zacks Research sharply cut near‑term EPS estimates across multiple quarters and fiscal years (many quarterly EPS moved to roughly $(0.07)–$(0.08); FY2026/FY2027 lowered to about $(0.29)), signaling weaker expected profitability and raising the bar for operational improvements — a key reason for downward pressure on the stock today.
• Negative Sentiment: Barrington trimmed its price target from $2.25 to $1.50; although the firm left a Buy rating, the lower target reduces measured upside and can weigh on short‑term trader sentiment. InsiderMonkey Article

Wall Street Analysts Forecast Growth

Several analysts have weighed in on OPK shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Barrington Research decreased their target price on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $2.03.

OPKO Health Price Performance

The company has a quick ratio of 3.52, a current ratio of 3.97 and a debt-to-equity ratio of 0.26. The stock’s 50 day moving average price is $1.23 and its two-hundred day moving average price is $1.34. The stock has a market cap of $850.16 million, a price-to-earnings ratio of -3.73 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. The company had revenue of $148.50 million during the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. The firm’s quarterly revenue was down 19.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.01 earnings per share. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Trading of OPKO Health

Hedge funds have recently modified their holdings of the stock. Caprock Group LLC purchased a new position in OPKO Health during the third quarter valued at approximately $26,000. Swiss Life Asset Management Ltd acquired a new position in OPKO Health in the third quarter valued at approximately $30,000. Zacks Investment Management purchased a new stake in OPKO Health in the 4th quarter worth approximately $27,000. Savant Capital LLC purchased a new stake in OPKO Health in the 3rd quarter worth approximately $33,000. Finally, StoneX Group Inc. acquired a new stake in shares of OPKO Health during the 4th quarter worth approximately $27,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.